ArticleAdvances in pharmacological and pharmaceutical sciences2025
Encapsulation of Curcumin and Gemcitabine: Cytotoxic Effect and Mechanisms of Death in Lung Cancer.
Article in Advances in pharmacological and pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the second most common type of cancer and the leading cause of cancer-related deaths worldwide. Some chemotherapeutic agents, such as curcumin and gemcitabine, have low bioavailability due to their hydrophobicity or the need for specialized transporters. This limits their cytotoxic potential against tumor cells but can be addressed through nanoencapsulation. This study evaluated the effects of nanometric encapsulation of curcumin and gemcitabine in chitosan, a biocompatible polymer, on the A549 lung cancer cell line and B16F10 murine melanoma cells. The chemical properties of the synthesized nanoparticles were characterized using UV-vis spectroscopy, Fourier transform infrared (FTIR) spectroscopy, and scanning electron microscopy (SEM). The nanoparticles ranged in size from 180 to 197 nm, with a positive surface charge between 11.8 and 16.3 mV. Cytotoxicity assays were conducted on the A549 and B16F10 cell lines, along with morphological analyses of apoptosis and flow cytometry to assess cell death mechanisms. Compared to the free drugs, the nanometric encapsulation of curcumin and gemcitabine did not always enhance the cytotoxic effects, but it did induce pronounced apoptosis in the lung cancer cells. These findings suggest that this approach could optimize drug delivery, reduce the required doses, and minimize side effects, thereby improving the overall efficacy of lung cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.